We have a great show for you this week!  Anisha Dua will be moderating a debate
between myself and Max Konig on this motion: "Hydroxychloroquine levels should be monitored in patients with SLE."  I learned a ton and thoroughly enjoyed it.  Be sure to vote on the post-debate twitter poll to decide the winner! 

This week I cover another of my meta-research projects, this one on systematic review and meta analysis (SRMA) growth as compared to randomized clinical trial (RCT) growth.  Short and to the point - hope you enjoy! I highly recommend checking out the associated graphs - just take a quick peek at some point while listening. Find them on my twitter handle @ebrheum 

Active comparator trial! Always my favorite.  Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs.  Check it out and let me know what you think! @ebrheum 

Another day, another lupus trial, another round of endpoint shenanigans.  Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble.  Hope you enjoy the episode!  Let me know what you think @ebrheum on twitter! 

Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message.  Also, check out the "2-5-10" rule that I referenced!  This is required reading for anyone who rotates with me - easily one of the most useful EBM papers I have ever read. 

Quick podcast this week that expands on issues I discuss in Episode 55.  Go back and listen to that one first if you have time!  I think this is an important issue and it's one I'd like to highlight.  Let me know what you think @ebrheum and please share with friends! 

This week I wanted to share a recent systematic review and meta analysis, which was published by myself and a group on behalf of the Global Rheumatology Alliance. I use this as an opportunity to close out a few issues and describe the current landscape.  After this I'm planning to go back to good old rheumatology-based podcasts for a few months! 

The podcast is back!  I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in! 

Back this week to update you on the data for hydroxychlorquine.  There has been a lot of action - and very little resolution - to this issue since my last episode.  Let me know what you think, follow along on twitter @ebrheum and get the papers themselves at ebrheum.com.  

Diving into a new "rheum treatments for COVID" topic today - IL6 inhibition. It took me awhile to get to this, in part because the hydroxychloroquine situation has been something to behold and in part because there's just nothing to say. I cover two case series here, neither of which are strong evidence. Hope you enjoy! Follow me @ebrheum to let me know what you think!